Search Weight Loss Topics:

Page 1,367«..1020..1,3661,3671,3681,369..1,3801,390..»

The Truth About Low Testosterone Levels, According to Experts – menshealth.com

Posted: October 11, 2019 at 10:51 am

Feeling tapped out. Foggy. Just not all that into sex. Gotta be your testosterone, ads would have you believe. And were believing it, too, with the number of T-supplement users tripling from the early 2000s through 2016.

Dont get us wrong: Testosterone is one critical hormone. Babies first encounter it in utero, when it triggers the differentiation of boys from girls. In puberty, it contributes to your bone growth and muscle mass, and continues to affect functions including your red-blood-cell production and mood stability.

But the message those ads are sending plays right into the economic and social anxieties men are facing. Its like when anti-anxiety meds such as Valium first came onto the scene, says urologist and MH advisor Elizabeth Kavaler, M.D. All these middle-aged women were addicted to Valium, because that was the solution to everything. Testosterone has become the new answer for a life of quiet desperation. More and more of us are feeling the exhaustion of uneasiness. We are being asked to do more with less. Were just trying to get through the day alive. Men think, Well, if I just get a little testosterone, Im going to feel great! Dr. Kavaler says. And thats not the case.

Theres so much information out there about Tmuch of it speculation and lorethat leads us to jump to conclusions about it. Men put all kinds of psychological weight on their testosterone numbera low one makes you think youre somehow less manly; a high one means youre basically LeBron Jamesand thats where we get things wrong. Theres little evidence for those stereotypes. Low doesnt automatically imply youre weak or retiring; high doesnt guarantee you muscles, aggressiveness, or MVP athletic performance.

A low number might not even be a low number for very long. It might just indicate that you havent been treating yourself very well. As long as your T is in the normal range, theres nothing about a high number thats better than a low one, or vice versa.

In the name of science and good journalism, I got my testosterone tested twice while writing this story. It put my assumptions up against a pretty big test, too (more on that later).

What do you really know about this famous hormone? Here, we break down the best and latest information to give you the clearest picture yet of what T means for you. And whether, maybe, you should be taking testosterone after all.

As many as 5 million men in the U.S. (generally older men) do actually have low levels of the hormone. To know if your testosterone is low, first see if you have any symptoms, which include: erectile problems, lack of energy (never feeling rested, no matter what you do; having a paunch; an AWOL libido (not just not wanting to have sex on a Thursday night after a crushing week, but lack of the kind of base-level sex drive wherein you get turned on by the sexy person you spot on the street, explains Tobias Kohler, M.D., of the Mayo Clinic).

With testosterone, as with life, normal is nuanced. And fraught (but shouldnt be). To get an accurate reading, you should have at least two tests, since testosterone is constantly in flux. It peaks in the morning, so if youre young and on a typical sleeping schedule, aim to be tested by 10:00 a.m. If youre over 50, it doesnt matter as much.

Be aware that your level can be affected by certain social factors and health habits. In the new book Testosterone: An Unauthorized Biography, scientists Rebecca M. Jordan-Young and Katrina Karkazis point out that T levels even respond to social factors like feedback. For instance, rugby players who watched video of good game plays and got positive feedback had up to a 50 percent increase in T compared with guys who were shown their mistakes and received critical assessments.

Resistance training can also give you a short-term boost in testosterone. Cardio doesnt elevate T levels as much in normal-weight men, says Jesse Mills, M.D., the director of the Mens Clinic at UCLA. But heres the thing: Jordan-Young and Karkazis dug through the research to find that T levels alone dont deserve the credit when it comes to an athletes performance. And cutting sleep short and taking multivitamins with biotin can push testosterone levels down (skip the vitamins for three days before testing).

So get your tests on days that are typical for you. And when you get your number, dont read too much into it. A T level of 264 to 916 nanograms per deciliter of blood is generally considered normal. If you are close to 264 and you feel fine, then youre no less healthy than a guy whose level is 700 and also feels fine. (Theres an exception to that, though: If your T level is below 300 and you have low-T symptoms, then docs would consider you in a low-T category)

Not reading into it is harder than it sounds. I got my first test at the tail end of a busy week. Id slept less than five hours the night before, then scrambled to the phlebotomist in a daze. My number: 287. Thats in the normal range, but just barely. I have no symptoms of low T, but it was hard to shake the feeling that there was something wrong with me, even though I know that normal is normal, no matter where it is in that range. Eleven days later, I was tested again. My number was 429. Why such a dramatic change? It might be because Id slept better and cut out my multivitamins.

Irrational or not, I felt like more of a man. The whole experience was a microcosm of our relationship with T. We act like its destiny, but its just biologyeasily misunderstood and more varied than we think.

The single best thing you can do to improve your level is be healthier. Avoid stress, get more sleep, and lose weightan enzyme in fat tissue converts testosterone to estrogen. Thats one reason flab can lower your T. Its also why overweight guys can develop man boobs, and why bodybuilders who juice can also develop man boobsthey dont have much fat, but theyve jacked their T levels so high that theres a lot of it available to be turned into estrogen. Thinking of T strictly as the male sex hormone oversimplifies the complex hormonal interactions that make our bodies work. Which is also why, if you can avoid it, you dont want to go with the needle-in-the-butt routine to raise your T.

But that might not work. If your level is low enough to warrant more aggressive treatment, your doctor can prescribe a drug that causes your pituitary to tell your gonads to make more testosterone. The typical choice is clomiphene citrate (Clomid), a common fertility drug for women. Using it doesnt exempt you from needing to get healthy, though, as it doesnt diminish the risk of losing T to bad sleep and a beer belly.

Then theres always testosterone-replacement therapy, which should be your last resort. (When you give your body T, it stops making its own, and theres no guarantee it can start again.) If, though, you and your doctor decide its the way to go, youve got options. You can try a testosterone replacement gel, a topical thats easy to use but can rub off on your partner or kids. There are pills, which are even easier to use than the gel and can deliver higher levels. Theres subcutaneous pellets, or rice-sized inserts that live directly under your skin. And then theres that needle in the butt, which can provide a major boost but is generally only used by docs who specialize in testosterone therapies.

Whatever you choose, be glad that weve moved past the early days of replacement therapies, like one in the 1920s that involved transplanting goat testicles into patients. Believe it or not, it didnt work, and it also didnt make anyone feel like more of a man.

See more here:
The Truth About Low Testosterone Levels, According to Experts - menshealth.com

Testosterone Replacement Therapy Market Overview, Analysis, Growth Opportunities and Forecast to 2025 – Pledge Times

Posted: October 11, 2019 at 10:51 am

The Testosterone Replacement Therapy market 2019 examines the global Testosterone Replacement Therapy market from a competitive outlook as well. Top Key Players of Testosterone Replacement Therapy are mentioned and a detailed competitive profile is presented for each of them.

The Global Testosterone Replacement Therapy report contains Market Revenue, Investment Opportunity, Market Features, Market Demand by Segment & Testosterone Replacement Therapy market Growth aspects. A wide variety of applications, Utilization ratio, Supply and demand analysis are also consist in the report. It shows manufacturing capacity, Testosterone Replacement Therapy Price during the Forecast period from 2019 to 2025. Testosterone Replacement Therapy Market by Key Players, Countries, Types and End Users, forecast to 2025 to its research database. This analysis is segmented on the bases of applications, types, technology and geography.

Access Exclusive Free Sample Report at: https://www.globalinforeports.com/request-sample/1071043

Our research analysts also have taken significant account facets and landscape scenario like Testosterone Replacement Therapy industry market placement plan frame, and competitive atmosphere for providing a competitive analysis.

Eli lilly, Pfizer, Endo International, Actavis (Allergan), AbbVie, Novartis, Teva, Bayer, Kyowa Kirin, Mylan

Get it in Discounted Price: https://www.globalinforeports.com/check-discount/1071043

North America, Asia-Pacific, UK, Europe, Central & South America, Middle East & Africa.

Any Query? Ask Our Expert at: https://www.globalinforeports.com/send-an-enquiry/1071043

Customization of this Report: This Testosterone Replacement Therapy report could be customized to the customers requirements. Please contact our sales professional (sales@globalinforeports.com), we will ensure you obtain the report which works for your needs.

Read the rest here:
Testosterone Replacement Therapy Market Overview, Analysis, Growth Opportunities and Forecast to 2025 - Pledge Times

Global Testosterone Replacement Therapy Market Analysis, Growth, Demand & Forecast 2019-2026: Endo International, AbbVie, Eli lilly, Pfizer,…

Posted: October 11, 2019 at 10:51 am

Report Testosterone Replacement Therapy covers all aspects of the "Testosterone Replacement Therapy Market". It provides basic market terminology and advanced analytical information in an understandable way that can be interpreted not just by a specialist but also a layman. One of the most important descriptions in this report is full information on the major key players Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals holding the market share. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps.

Click here to access the Sample report: http://www.99strategy.biz/global-and-north-america-testosterone-replacement-therapy-market.html#request-sample

The market growth rate in around the globe can vary from region to region, for which the report presents the full analysis based on different geographic areas. Information on the technical tactics that are followed in the market, applications are provided exclusively in the Testosterone Replacement Therapy report. At the same time, the report provides data analyzed based on cost structure statistics for raw material collection, efficient product manufacturing, safe delivery, and overall after-sales costs.

The global Testosterone Replacement Therapy report also contains detailed information on important, less significant growth and limitation factors that significantly affect market growth. The strike of the global Testosterone Replacement Therapy market is mentioned in the part of those areas, It demonstrates various segments Gels, Injections, Patches, Others and sub-segments Hospitals, Clinics, Others of the global Testosterone Replacement Therapy market. The report also provides comprehensive information on the income of top market owners, their annual transactions, the stability of their actions and the strategies used to attract the activity. The report also highlights some of the rules and regulations that have been established by the governing bodies of some countries that can stimulate and restrict commercial activities in certain parts of the world.

Read Detailed Index of full Research Study at:: http://www.99strategy.biz/global-and-north-america-testosterone-replacement-therapy-market.html

The information available in the Testosterone Replacement Therapy market summarized report provide customers with effective information that enables them to make effective decisions, which could lead to a significant expansion of the business in the future.

There are 15 Chapters to display the Global Testosterone Replacement Therapy market

Chapter 1, Definition, Specifications and Classification of Testosterone Replacement Therapy , Applications of Testosterone Replacement Therapy , Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Testosterone Replacement Therapy , Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Testosterone Replacement Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Testosterone Replacement Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Testosterone Replacement Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Gels, Injections, Patches, Others, Market Trend by Application Hospitals, Clinics, Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Testosterone Replacement Therapy ;Chapter 12, Testosterone Replacement Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Testosterone Replacement Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

Enquire Here Get customization & check discount for report @: http://www.99strategy.biz/global-and-north-america-testosterone-replacement-therapy-market.html#inquiry-for-buying

Sorry! The Author has not filled his profile.

Read more from the original source:
Global Testosterone Replacement Therapy Market Analysis, Growth, Demand & Forecast 2019-2026: Endo International, AbbVie, Eli lilly, Pfizer,...

Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism – Seeking Alpha

Posted: October 11, 2019 at 10:51 am

Introduction

Mereo BioPharma (MREO) is a British small-cap ($62M) biopharma developing therapeutics for rare disorders as well as endocrine and oncological diseases. MREO has a diverse pipeline including MPH-966 (alvelestat), BCT-197 (acumapimod), and OMP-305B83 (navicixizumab) for alpha-1 antitrypsin deficiency, chronic obstructive pulmonary disease, and ovarian cancer, respectively. The focus of this article is BGS-649 (leflutrozole), a drug asset licensed from Novartis (NVS) that is in clinical development for treating hypogonadotropic hypogonadism (Hypo-H).

Hypogonadism is a medical condition characterized by a deficiency in testosterone, the primary male circulating sex hormone synthesized in the gonads. Hypogonadism can present itself during fetal development, before puberty or during adulthood. Testosterone is important in the development and maturation of reproductive tissues. Symptomatic events of this disorder are decreased libido, impaired erectile function, muscle weakness, increased adiposity, depressed mood, and decreased vitality.

Hypogonadism can be triggered by a primary testicular disorder (hypergonadotropic; Hyper-H) whereas hypogonadotropic hypogonadism (Hypo-H) is a consequence of congenital or acquired diseases that affect the hypothalamus and/or the pituitary gland.

The hypothalamus (i.e. brain), pituitary (i.e. endocrine), and gonadal (i.e. reproductive) glands are all often known as hypothalamic-pituitary-gonadal axis because they all act in concert in the development and regulation of the reproductive and immune systems. Any alteration in this axis induces changes in the hormones produced by each gland that can affect their various local and systemic effects on the body. Hypo-H is frequently reported in metabolic disorders such as obesity, type 2 diabetes, and metabolic syndrome.

Men who present with Hyper-H do not respond to hormone replacement medication because the disorder is caused by primary testicular failure. Testosterone hormone replacement is the mainstay treatment for Hypo-H to normalize testosterone levels and restore fertility. Alternative options include gonadotropin therapy regimen to induce endogenous testosterone, aromatase inhibitors, and selective estrogen receptor modulators.

BGS-649 (leflutrozole) is a novel once-weekly oral aromatase inhibitor in clinical development as first-line therapy for the treatment of Hypo-H in obese men. The thesis is that BGS-649 normalizes testosterone levels by inhibiting aromatase and is, therefore, expected to improve the related conditions. The premise is that lower levels of testosterone in obese men with Hypo-H is driven by high levels of the aromatase enzyme in fat tissue which irreversibly converts testosterone into estradiol. Aromatase inhibitors are widely used therapeutically in breast cancer.

Clinical Data: A Phase 2b clinical trial of BGS-649 in 271 patients with Hypo-H achieved its primary clinical endpoint of total testosterone normalization:

in over 75% of subjects after 24 weeks of treatment, and in at least 90% of patients after 24 weeks at the two highest doses. All three doses met all secondary endpoints, including the improvement of testosterone luteinizing hormone (LH.) and follicle stimulating hormone (FSH.) levels. The exploratory endpoint of improvement in total motile sperm count was also met.

A safety extension study completed in 143 patients successfully demonstrated that none of the doses of BGS-649 met the lower bound (95% confidence interval) of the pre-specified safety criterion of a greater than 3% reduction in lumbar spine bone mineral density (BMD) after 48 weeks of treatment. The extension study also demonstrated normalization of testosterone in more than 90% of the patients at all three doses and maintenance of the effects on LH and FSH.

Individuals with Hypo-H lack or have low levels of gonadotropin-releasing hormone (GnRH.). GnRH is a peptide hormone secreted from the hypothalamus and stimulates gonadotropic cells in the anterior pituitary gland to release LH and FSH for normal gonad function including testosterone production by the testes. The observation that BGS-649 therapy was associated with normal FSH and LH levels in the Phase 2b study could suggest these patients also had GnRH levels normalized or elevated.

The prevalence of Hypo-H was estimated to be 1:10,000 to 1:86,000 individuals 20 years ago - meaning the prevalence could be higher due to increasing rates of obesity.

Upcoming catalytic events are:

Setrusumab for Osteogenesis Imperfecta (OI.)

12-month data from Phase 2b ASTEROID study in adult OI patients expected in Q4 2019. In May 2019, Mereo reported positive 6-month interim data from the fully-enrolled ASTEROID study. These data were accepted for a late-breaking oral presentation at the upcoming American Society for Bone and Mineral Research (ASBMR) 2019 Annual Meeting to be held from September 20-23 in Orlando, FL, USA. The Company expects to report 12-month topline data from the blinded portion of the study in Q4 2019. There are currently no FDA or EMA-approved treatments for OI.

Pivotal pediatric study ready in the EU and Canada. In addition to evaluating setrusumab in adult OI patients, Mereo's Paediatric Investigation Plan (PIP) has been approved by the EMA and a study design has been agreed for a pivotal registration trial in children. Mereo is also exploring an extension of the planned pivotal study into the U.S.

Alvelestat for Severe Alpha-1 Antitrypsin Deficiency (AATD.)

Enrollment continuing for the Phase 2 proof-of-concept study in severe AATD patients with topline data expected in mid-2020. If the results are positive, Mereo intends to commence a pivotal trial in the EU and the U.S. in AATD as soon as possible thereafter.

Investigator-sponsored clinical studies underway in AATD and also in bronchiolitis obliterans syndrome (BOS) as a result of graft-versus-host disease (GvHD) in patients undergoing hematopoietic stem cell transplantation (HSCT). BOS is an orphan disease characterized by inflammatory obstruction of the lung's tiniest airways and is the primary cause of death in patients who receive lung transplants. Based on the preliminary clinical data to-date, Mereo intends to investigate the use of alvelestat to treat patients with BOS following a lung transplant.

Partnering Discussions Continue for Broad Portfolio of Clinical-Stage Programs

Leflutrozole for Hypogonadotropic Hypogonadism .. Following the positive Phase 2b and six-month extension data reported in 2018, earlier this year Mereo held an advisory board to consider the future development strategy for leflutrozole, with a focus on the positive effects on semen parameters. Mereo has decided that future product development will focus on male fertility.

Acumapimod for Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is Phase 3-ready following a successful Type B End of Phase 2 meeting with the FDA and agreed outline for a pivotal Phase 3 clinical trial program. Recently, a positive Scientific Advice Working Party (SAWP.) also took place with the EMA.

Navicixizumab for Advanced Platinum-Resistant Ovarian Cancer. In July 2019, Mereo held a successful Type B End of Phase 1 meeting with the FDA regarding a potential pathway for accelerated approval for navicixizumab for the treatment of patients with advanced ovarian cancer. Mereo and the FDA discussed, and agreed in principle, an outline for the design of a Phase 2 clinical trial that could potentially support the accelerated approval of navicixizumab in patients with ovarian cancer (including peritoneal or fallopian tube cancer) who have become resistant to prior therapies.

Etigilimab for Advanced Solid Tumors. Etigilimab has completed a Phase 1a/b trial of etigilimab, administered as either a single-agent or in combination with nivolumab, in patients with advanced or metastatic solid tumors.

The biggest risk is the low cash reserve. As highlighted above, MREO is seeking partnership agreements for some of its clinical programs. Partnership agreements would provide the financial stability needed to advance its clinical pipeline.

At the end of Q2/2019, it reported cash, cash equivalents, and short-term investments of $45.06M (after conversion from pounds sterling). Institutional ownership currently stands at 1.88%, with 43 institutional holders accounting for 1,805,180 total shares. Analysts recommend a buy with an average price target of $7.20.

CEO Dr. Denise Scots-Knight on the future:

Our team remains focused on advancing discussions with potential partners to help us further realize the value of these assets and we look forward to updating you regarding these discussions in the future. In addition to the progress have highlighted regarding our development programs, we also continue the build out of our senior Management Team and board of directors to ensure that we have the necessary expertise and are well positioned as our programs continue to advance.

Thanks for reading. While I occasionally cover companies like this, my focus remains investment opportunities in liver therapeutics, specifically NASH and Cholestatic liver diseases, which are exclusive to members of my private investing community, Liver Therapy Forum Marketplace.

As a Ph.D. trained liver biomedical scientist & Scientific Consultant, I provide:

Novel mechanistic insights and "updating thesis" highlighting promising drug candidates.

Exclusive access to full-length in-depth research analytical articles, KOL interviews, newsletters/digests, and Q & A chat board.

Actionable events to minimize risks and grow your investments.

Knowledge and wisdom required to understand the diverse and complex NASH therapeutics landscape.

Sign-up today to grow your investments!

Disclosure: I/we have no positions in any stocks mentioned, but may initiate a long position in MREO over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: As always, my articles are meant to facilitate your understanding. Readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. Investing in common stock can result in partial or total loss of capital. Please implement due diligence and invest wisely.

See the original post:
Mereo BioPharma And Leflutrozole In Hypogonadotropic Hypogonadism - Seeking Alpha

Global Testosterone Replacement Therapy Market Growth Ratio Analysis with Top Prominent Players like AbbVie, Endo International, Eli lilly, Pfizer,…

Posted: October 11, 2019 at 10:51 am

We, Market Research Store, after comprehensive analysis, have introduced a new research study on "Global (United States, China, and European Union) Testosterone Replacement Therapy Market Research Report 2019-2025." A section of the report serves with in-depth information on Product Types [Gels, Injections, Patches], Applications [Hospitals, Clinics] and Key Players [AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals]

Another section of the report particularly focuses on delivering wide-ranging analytical information on regional segmentation, which includes North America, Asia-Pacific, Middle East & Africa, Europe, and Rest of the World. Apart from this, manufacturing protocols, costing, development plans & policies, current trends, dynamics, clear market terminologies, and classifications, are very well described in the report. The researchers team presents the analytical data and figures in the report in an effectual way with the help of graphs, diagrams, pie charts, and other pictorial illustrations.

If you are managing a Testosterone Replacement Therapy manufacturing company and handling imports-exports then this published piece of article will surely assist you in understanding the sales volume with impacting trends.

To Get FREE PDF Sample Pages of Testosterone Replacement Therapy Market Report, click @ http://www.marketresearchstore.com/report/global-testosterone-replacement-therapy-market-report-2019-503949#RequestSample

Important Points Mentioned In The Testosterone Replacement Therapy Market Study

Manufacturing Analysis: The report comprises descriptive information after analyzing multiple segments of Testosterone Replacement Therapy market, which include product type and applications, among others. The Testosterone Replacement Therapy market report includes a separate chapter emphasizing thorough analysis of the manufacturing process authenticated via primary information gathered from key officials of reputed industries and several industry analysts.

Sales and Revenue Estimation: By implementing several top-down and bottom-up approaches on the historical sales & revenue data and the current market status, the researchers have forecasted the market growth and size in key regions. Moreover, the report includes a comprehensive study on classified and prominent types as well as end-use industry. The report even provides significant information related to regulatory policies and macroeconomic factors that determine Testosterone Replacement Therapy industry evolution and predictive analysis.

Demand & Supply Assessment: Testosterone Replacement Therapy report also offers important information on product & service distribution, manufacturing, Consumption, and Export & Import (EXIM) ** if applicable.

Competitiveness: The Testosterone Replacement Therapy report provides key information based on the product portfolio, company profile, product & service cost, potential, and sales & revenue generated by the global and regional leading companies.

Enquire Here For Discount Or Report Customization@ http://www.marketresearchstore.com/report/global-testosterone-replacement-therapy-market-report-2019-503949#InquiryForBuying

SWOT Analysis of Leading Contenders: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus PharmaceuticalsMarket Growth by Types: Gels, Injections, PatchesMarket Growth by Applications: Hospitals, Clinics

Introduction about Global (United States, China, and European Union) Testosterone Replacement Therapy Market

To order the research study Global (United States, China, and European Union) Testosterone Replacement Therapy Market Research Report 2019-2025, click here @www.marketresearchstore.com/report/global-testosterone-replacement-therapy-market-report-2019-503949

Sorry! The Author has not filled his profile.

Read this article:
Global Testosterone Replacement Therapy Market Growth Ratio Analysis with Top Prominent Players like AbbVie, Endo International, Eli lilly, Pfizer,...

Hypogonadism Treatment Market to Witness an Outstanding Growth by 2017 2025 – Space Market Research

Posted: October 11, 2019 at 10:51 am

Hypogonadism is defined as hormonal disorder in which the glands (gonads & ovaries) produce little or no hormones causing its deficiency in the body. Hypogonadism in males refers to deficiency of testosterone due to dysfunction of either of the testes. Female hypogonadism refers to deficiency of estrogen or progesterone due to reduced activity of the ovaries. Hypogonadism is classified into two types: primary hypogonadism (testicular failure) and central hypogonadism (hypothalamic-pituitary axis dysfunction). Other major causes of hypogonadism include autoimmune disorder, genetic disorder, severe infections, and liver and kidney diseases. Generally, hormone and imaging tests are used to diagnose hypogonadism.

According to the Boston University School of Medicine, around 4 million to 5 million men in the U.S. were affected with hypogonadism in 2003. The incidence of hypogonadism in men aged between 40 years and 69 years in the country is around 481,000 new cases per year. According to the European Male Aging Study, the prevalence of late onset hypogonadism in men aged between 40 and 79 was 2.1% in 2016. Studies suggest that hypogonadism in adult men is often underdiagnosed and undertreated and only 5%. According to the Urology Care Foundation, hypogonadism is a chronic condition which would require lifelong treatment. The treatment for hypogonadism depends on the cause and concern about fertility and includes treatment such as hormone replacement therapy or assisted reproduction.

Men with heart disease, HIV, COPD, or renal disease have high prevalence of hypogonadism. Factors such as rising prevalence of type 2 diabetes and obesity further increase the incidence of hypogonadism. Growth of the global hypogonadism treatment market is attributed to rise in geriatric population, increase in infertility, and improved diagnosis. However, growing concerns about the potential side effects, availability of generic drugs, and preference for other natural hormonal boosters and supplements are likely to hamper the growth of the hypogonadism treatment market. Increasing awareness, awaiting approvals for new generation drugs in pipeline, and technological advancements present significant opportunities in the hypogonadism treatment market.

The primary treatment option for hypogonadism is hormone replacement therapy. Based on product type, the market has been classified into testosterone replacement therapy, estrogen therapy, and progesterone therapy. Testosterone replacement therapy is the fastest growing segment as hypogonadism is more prevalent in men. The segment is expected to hold major share of the global market during the forecast period.

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/hypogonadism-treatment-market.html

In terms of mode of administration, the hypogonadism treatment market has been broadly classified into transdermal patch, topical gel, buccal tablets, implantable pellet, intramuscular injections, and oral tablets. Transdermal patch followed by topical gels are anticipated to be the fastest growing segments as these provide steady route of administration and are easily modifiable over a short period of time. The oral and buccal tablets segments are anticipated to experience sluggish growth during the forecast period due to high side effects and liver diseases.

Based on the distribution channel they are segmented into hospital pharmacies, retail pharmacies and others. The major market share for the hypogonadism treatment market is for the retail pharmacies segment and is anticipated to rule the market during the forecast period as continuous long term treatment is required for the hypogonadism patient.

In terms of region, the global hypogonadism treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest market for hypogonadism treatment, accounting for more than half of the market share due to the factors such as increased adoption of newer highly advanced products, rising awareness about hormonal disorder including various treatment options available, and advancing health care infrastructure. However, Asia Pacific is anticipated to be the fastest growing market during the forecast period due to increasing urbanization and rise in the patient population.

Key players in the global hypogonadism treatment market are Bayer AG, Abbott Laboratories, Inc., Merck Serono, Sanofi, Merck & Co., Inc., Actavis, Inc., AbbVie Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Endo International plc, Ferring Holding S.A., and Laboratoires Genevrier.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=30392&source=atm

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=30392&source=atm

Original post:
Hypogonadism Treatment Market to Witness an Outstanding Growth by 2017 2025 - Space Market Research

Parties must deepen Diet debate by taking national interest into account – The Advocate

Posted: October 11, 2019 at 10:49 am

The following editorial appeared in Friday's Japan News-Yomiuri:

- - -

It is imperative to discuss domestic and foreign issues from a comprehensive perspective with a view to protecting the national interest.

Full-scale debate between the ruling and opposition parties has begun at the House of Representatives Budget Committee. A focal point was a new trade agreement concluded by Japan and the United States.

While tariffs on agricultural imports from the United States were lowered, it was agreed not to invoke additional tariffs on U.S. automobile imports from Japan.

Yuichiro Tamaki, leader of the Democratic Party for the People, denounced the deal, saying that it "amounts to Japan alone conceding on tariffs on agricultural imports." He also pointed out that the prevention of additional tariffs was not documented in the agreement. Prime Minister Shinzo Abe refuted this, saying: "It was confirmed during a meeting with U.S. President Donald Trump. It represents a serious promise."

The accord was reached after holding repeated negotiations right up until the last moment with the Trump administration, which champions an "America First" policy. The government needs to carefully explain in detail the content and significance of the agreement, thereby seeking the people's understanding of the trade deal.

Promoting free and open trade serves Japan's national interest. It is essential to exchange views on trade policies from a broad perspective, including on how to draw the United States back to an international cooperation framework.

During an interpellation session, Tamaki also brought up a recent incident in which a patrol vessel of the Fisheries Agency and a North Korean fishing boat collided. He cast doubt on the government's act of returning rescued North Korean fishermen without questioning them over the incident.

Abe explained that this is because it could not be confirmed that there had been illegal fishing.

To ensure stability in this region of the world, it is indispensable to eliminate North Korean threats. How can U.S.-North Korea talks be backed up and denuclearization realized? The opposition parties should develop their argument by delving into how foreign measures will be taken vis-a-vis Pyongyang.

In regard to constitutional revision, Tamaki insisted that the Liberal Democratic Party drop its proposal to add the legal grounds for the Self-Defense Forces by amending Article 9. Abe did not go beyond saying that "it is important to stipulate the SDF in Article 9."

It is highly significant to stipulate the SDF, which is tasked with ensuring national security, in the nation's top law, thereby sweeping away the argument that the SDF is unconstitutional. Individual parties are called on to discuss what provision should be stipulated by presenting their views at the commissions on the Constitution in both houses of the Diet based on the LDP proposal.

The opposition parties also took time to raise the scandal involving executives of Kansai Electric Power Co. who received money and goods. They condemned the Economy, Trade and Industry Ministry, saying that it did not fulfill its responsibility as a supervisory office.

Economy, Trade and Industry Minister Isshu Sugawara responded by saying: "Utility firms undertake business that has extremely high public interest. So we'll supervise them strictly."

KEPCO plans to establish a third-party panel to reinvestigate, among other things, what actually happened in the scandal involving the receipt of money and goods. The Diet should deepen debate on electric power policy without concentrating only on the scandal.

Originally posted here:
Parties must deepen Diet debate by taking national interest into account - The Advocate

Madonnas Secret Weapon: The Real-Life Diet of Loic Mabanza – GQ

Posted: October 11, 2019 at 10:49 am

I also cut out sugar, which is very hard, because I love sugar. But being gluten-free really helped me with the discipline. But I did it, so I was, like, You know what? Sugar is the same. And I really felt the difference. Even with fruit. I eat berries, watermelon, and apples, but the rest is a little bit too much sugar, because I feel the effect that it has on my body.

Madonnas been going on at 10 or 11, and Ive heard even midnight on weekends, which means the show can run until 3 a.m. How do you manage to get enough sleep when you're ending so late? Do you shift back your whole sleeping schedule?

This is the hardest part, but it's become easier. It was actually worse during rehearsals, because the time we finished would change a lot, but now it's a little bit more consistent, so I try to keep at least eight hours of sleep a day. I do a lot of activities, I love moving, I love doing a lot of stuff at once. I'm doing a lot of extra things outside of this tour. I utilize the time that I'm not working to have other meetings, close some deals, and the like. So I really need my eight hours. But if I'm not on tour, sometimes with six hours I'm fine.

I work just as hard when I'm not on tour. I'm also a filmmaker and an actor. I can spend, like, 10 hours a day working on a script. I'm always creating.

Do you do anything else to keep your energy levels up throughout the night for this tour?

No, we're already so pumped. I do what I love! I'm onstage with some creative geniuses around me and an amazing crowd, and we're doing an amazing show. That's enough to give me a bunch of energy. I'm actually overflowing. I'm so pumped all the time, every number.

Are you naturally a night owl?

When I first started dancing, I would dance all night every night, and then I would sleep at school. So I find a lot of inspiration at night, but now I know why: it's because nobody's awake, so it feels like the world is yours. I realized that if I wake up very early in the morning, it's the same thing. Because nobody's awake, you have the time for yourself, you have nobody putting you in their agenda to do whatever. Its your own time. So now when I write, I work very early in the morning.

When you get home from such an energy-packed night, whats the first thing you do to get yourself ready for sleep?

I like to unwind. First I order food from whatevers open, and then I take a shower. Most days, I read a book, but sometimes Ill see some friends. I like to socialize, and I think its very important for me to keep a great social life.

What are you reading right now?

I always read three books at the same time. I just finished reading a book called Finished, which basically explains why people don't really finish stuff. They always start something, whether it's a project, a diet, a relationship or whatever, but they never finish. I believe in the theory that perfection is the enemy of execution, because people have the mentality of all or nothing, and if it's not all, they just stop. So sometimes you just have to finish it, even if it's not perfect, even if it's not good. And then you can even come back to it, or it can be just good enough.

Read more here:
Madonnas Secret Weapon: The Real-Life Diet of Loic Mabanza - GQ

The Good And Bad In Your Diet: Know What You Should Eat And What You Shouldn’t To Stay Fit And Healthy – NDTV News

Posted: October 11, 2019 at 10:49 am

Healthy diet: There exists both good fat and bad fat, and good carbs and bad carbs

Whenever you hear the term "diet", it inadvertently infers some kind of restriction in your diet that you cannot get away with. However, the truth is that your diet can include all foods, as far you know the difference between the good and the bad in your diet. Highlighting the same is nutritionist Nmami Agarwal in her blog post shared on Instagram. "The very nature of diets is to train us to think of the foods as good foods and bad foods because they supposedly make us gain weight or cause all sorts of health conditions," she writes in her post.

If you want to lose weight or maintain a healthy weight, then you must include all food groups in your diet-fats, carbs and protein. With the coming of fad diets like keto diet, low-carb diet and low-fat diet to name a few, many people have come to believe that eating fats and carbs can make them gain weight.

The truth, however, is that cutting on your fats and carbs may help you with quick weight loss. But, this weight loss is temporary in nature and is likely to bounce back the minute you resume regular eating habits.

Low-carb and low-fat diets can make you feel starved, fatigued and irritablePhoto Credit: iStock

Fats, carbs and protein are important macro nutrients that should be a part of your diet. However, there are good carbs and bad carbs, and there is good fat and bad fat. Here's what you should know...

Also read:Essential Nutrients You Need For Losing Weight Quickly

Simply put, saturated fats are the bad fats with no nutrient value. They are the ones that cause weight gain and increase your calorie intake. Unsaturated fats are the good fats, the kind of fats that provide you energy and also keep your body warm. High fat dairy, red meat, ice cream, butter, chips, and cheese are foods that are high in saturated fat. Eating saturated fats in excess can increase bad cholesterol level. High cholesterol levels can put you at risk of heart disease.

There is also something called trans fat, which are usually found in partially hydrogenated vegetable oils. Monounsaturated fats (MUFA) and polyunsaturated fats (PUFA) are fats found in avocado, avocado oil, olive oil, canola oil, fatty fish, nuts and seeds. These are also healthy fats that must be a part of a healthydiet.

Also read:5 Go-To Foods For Times You Are Feeling Stressed Or Under Pressure

Simple or refined carbs are bad carbs while complex carbs are good carbs that should be in your diet. Simple carbs consist of only one or two sugar molecules. They rapidly increase blood sugar levels. Processed foods like white sugar, candy, desserts, syrups and sugar-sweetened beverages like soda are all high in refined carbs. Simple carbs slow digestion and lack nutritive value.

Complex carbs, on the other hand, are the ones present in foods like legumes, grains, peas, potatoes, fruits and vegetables. Complex carbs are healthy carbs that are required to fulfil your satiety, make you feel energised. Brown rice, quinoa, barley, oatmeal and other whole grains are fibre-rich carbs that must be a part of a good diet.

Fresh fruits and vegetables contain fibre-rich carbs that you must include in your dietPhoto Credit: iStock

Also read:Walnuts, Flaxseeds And Other Best Foods To Lower Your Numbers

Protein-rich foods are important in weight loss diet. They help in building muscles and also help in keeping you full for longer. Proteins are known to be building blocks of the human body. However, excess intake of proteins can be detrimental to health. Some common side effects of high protein diet include weight gain, constipation, bad breath, diarrhoea and kidney damage. Also, both vegetarian and non-vegetarian diet can provide you with sufficient protein. Eggs, nuts and seeds, chicken breast, milk, cheese, yogurt, cottage cheese, broccoli and other leafy green vegetables are protein-rich foods that you must include in a healthydiet.

(Nmami Agarwal is nutritionist at Nmami Life)

Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.

Get Breaking news, live coverage, and Latest News from India and around the world on NDTV.com. Catch all the Live TV action on NDTV 24x7 and NDTV India. Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.

Read more:
The Good And Bad In Your Diet: Know What You Should Eat And What You Shouldn't To Stay Fit And Healthy - NDTV News

How to get rid of belly fat: Woman reveals the diet plan she followed to lose two stone – Express

Posted: October 11, 2019 at 10:49 am

Sharing her before and after transformation images to Reddit, the woman was ecstatic to reveal she had lost 30 lbs (two stone and two pounds). The poster, known as meowitsmichelle said she wasn't completely done with her weight loss journey. She revealed she lost the weight by a change in her diet. There was one particular diet the poster used to help her shed the weight - the keto diet.

Responding to questions about her diet on a Reddit thread celebrating people who have lost weight following the keto diet, meowitsmichelle wrote: My biggest change has just been how I look at food.

"Every meal was pasta, bread, rice and then multiple times a week washing it all down with 4-8 Coronas.

"Not to say Ive stopped drinking, but have switched to the Claws lol."

White Claw is a brand of low calorie alcoholic drink that has become popular in the USA in recent months.

It is not yet available to buy in the UK, but comes in six different flavours in America.

The Reddit poster explained she hadn't finished on her weight loss journey, and explained: "My ultimate goal was to be under 160 but once I hit that I changed it to be around 140."

The Keto diet has become wildly popular in recent times, and many people - celebrities and normal people alike - with many sharing their tips and tricks.

One of those celebs is Jonathan Ross, who followed the keto diet to lose two stone.

Speaking in 2015, Ross said he cut out sugar and carbs in a bid to slim down. He said: My wife wanted to go on an eating plan so you can actually maintain it, but also really enjoy food."

Rather than paying an expensive nutritionist, Ross revealed he surfed the internet for diet inspiration.

It was then he discovered the keto diet - popular with many weight loss devotees online.

He said: A lot of them [Reddit users] were talking about a diet called Keto. It's a bit like Atkins but more scientific.

It's mostly meat and fish, lots of egg and cheese. You have a lot of cauliflower. There is a lot of work involved so I watch them working quite hard in the kitchen and eat everything they've made."

What exactly can you eat on the keto plan?What macros should followers aim for?

Rafael Rozenson, nutritional expert and founder of http://www.Drink-Vieve.co.uk, said: "For those wanting to lose weight, you may want to start your ratio at 40 per cent carbs, 40 per cent protein and 20 per cent fat.

The expert added if weight loss is your main goal, it is important that you eat fewer calories than your maintenance calories intake.

Read more:
How to get rid of belly fat: Woman reveals the diet plan she followed to lose two stone - Express


Page 1,367«..1020..1,3661,3671,3681,369..1,3801,390..»